Navigation Links
Another Top 10 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac
Date:4/22/2010

iCardiac Now Providing Services to Five of the Top Ten Pharmaceutical and Biotechnology Companies

Rochester, New York (PRWEB) April 22, 2010 -- iCardiac Technologies, Inc., a provider of next generation cardiac core lab services, announced today that a top 10 pharmaceutical company has awarded iCardiac a cardiac safety study leveraging iCardiac’s COMPAS technology platform including advanced ECG biomarker analyses.

"The industry is entering a period of accelerating conversion from outdated cardiac safety evaluation methods to more advanced, sophisticated techniques," said Sasha Latypova, Executive Vice President. "Drug cardiac safety is rapidly evolving with tougher standards imposed by the regulators. We are proud to be able to leverage iCardiac’s team of experts and our advanced technologies to deliver the next generation of advanced ECG analytics and services for improving the precision, accuracy and resource efficiency of global cardiac safety studies."

In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision, high rate of false positives/negatives and high cost of the “gold standard” manual or semi-automated QT measurements has lead to efforts toward providing more advanced cardiac safety analytics.

About iCardiac Technologies
iCardiac Technologies, Inc., provides drug development companies worldwide with the complete range of next generation cardiac safety core lab services. Its team of cardiac safety experts collectively bring over 100 years of cardiology, electrophysiology, drug development, regulatory and academic experience. The iCardiac team pioneered the field of Highly Automated QT evaluation as well as controlling for autonomic nervous system effects on the QT interval, a phenomenon estimated to produce false-positive results in conventional QT studies for as many as 25% of all molecules currently in clinical development. iCardiac’s services are supported by the COMPAS technology platform which maximizes the precision and decreases the cost of cardiac safety assessment from First-in-Human studies to Phase III studies. This suite of tools, which complies with the FDA’s ICH E14 QT/QTc guidance for Through QT Studies (TQT), was originally developed and validated at the University of Rochester’s Heart Research Follow Up Program (HRFUP), as well as in Pfizer’s Research and Development programs. iCardiac’s analytics have been used for over a decade in support of clinical trials.

# # #

Read the full story at http://www.prweb.com/releases/2010/04/prweb3898644.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. The MedZilla Report for April 2010 - Pharma Layoffs Drop Below 400 in March; Health Care Adds Another 27,000 Jobs
2. Bone Biologics Announces Another Round of Equity and Debt Investment by Musculoskeletal Transplant Foundation and the Addition of Board Member, Mark Spilker
3. Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services
4. The MedZilla Report for August 2009 -- Health Care Grows Another 28,000 While Hospitals And Insurers Feel Painful Pinch
5. The first DFG research centers to be funded for another 4 years
6. GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
7. OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services
8. Cephalon Reports Another Strong Quarter
9. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
10. Diverse Coalition of Purchasers Respond to BIO CEO Fly-In: There is Another Side to The Story
11. Another industry first enabled by Benchmark Biolabs - Peros oral delivery platform and vaccine facility licensed by the USDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  Only nine percent of ... over profits, while only 16 percent believe health insurance ... today. Meanwhile, 36 percent of U.S. adults believe health ... over profits, compared to hospitals (23%). "We ... said Wendy Salomon , vice president of reputation ...
(Date:1/17/2017)... ... January 17, 2017 , ... One Million Solutions in ... $3 million in investment towards 15+ TEC Validation Projects™. As a pre-competitive consortium, ... applicability in drug safety assessment, for the industry as a whole. , Through ...
(Date:1/17/2017)... , Jan. 17, 2017  On January 10 ... 35th Annual J.P. Morgan Healthcare Conference in ... D. Kittle, Jr. , spoke to pharmaceutical leaders and ... by ProclaRx to break down and destroy biofilms.  ... bacteria and prevent antibiotics and the body,s immune system ...
(Date:1/16/2017)...  Eurofins Genomics today announced the expansion of its ... receive their primers in a shorter turnaround time, without ... with other providers. Express oligos are available for anyone ... no additional fee. Researchers use the oligos ... sequencing, genotyping, site-directed mutagenesis, and cloning. Often, they are ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow at ... report has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
(Date:12/15/2016)... -- "Increase in mobile transactions is driving the growth ... is expected to grow from USD 4.03 billion in ... CAGR of 29.3% between 2016 and 2022. The market ... for smart devices, government initiatives, and increasing penetration of ... expected to grow at a high rate during the ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
Breaking Biology News(10 mins):